ArticleMultiple sclerosis journal - experimental, translational and clinical
Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infusion-related reactions (IRRs) are a common side-effect of ocrelizumab (OCR), with the highest risk occurring during treatment initiation. To minimize IRR risk, the first dose is split into two 300 mg infusions over two weeks. Subsequent doses are administered every six months as a 600 mg infusion. After treatment interruptions, some physicians restart with two separate 300 mg infusions due to concern about IRRs. This study evaluates IRR occurrence following a 600 mg infusion after extended treatment interruption. Methods: This retrospective cohort study included all multiple sclerosis (MS) patients who received at least one 600 mg OCR infusion between June 2018 and January 2024 at Amsterdam UMC. Infusions were categorized by interval duration: normal (6 months), moderate (7-9 months) and long (>9 months). Logistic regression analyzed the IRR occurrence. Results: 1438 infusions, in 275 patients, were analyzed. Neither the moderate interval group (306 infusions, OR = 0.914, Conclusion: Despite the retrospective design and smaller sample sizes in the moderate and long interval groups, our findings indicate that administering OCR as a single 600 mg infusion after a prolonged interval is safe regarding IRR occurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.